Iga K, Ogawa Y, Toguchi H
Pharmaceutics Research Laboratories, Takeda Chemical Industries, Ltd., Osaka, Japan.
Pharm Res. 1992 May;9(5):658-62. doi: 10.1023/a:1015858228394.
To evaluate the rate of drug release at the tumor and maximal drug targeting after administration of thermosensitive liposomes with hyperthermia, a theoretical and experimental method was derived assessing the fraction of drug released from liposomes in a single pass through the heated tumor, F, and the drug targeting index when drug release occurs completely in response to heat (F = 1), DTImax. The F and DTImax were evaluated for four types of liposomes (LUV-1 and LUV-2, thermosensitive large unilamellar liposomes; LUV-3, a nonthermosensitive large unilamellar liposome; and SUV-1, a thermosensitive small unilamellar liposome) using reported data on blood liposome levels and tumor drug levels after the liposomes were administered to tumor bearing mice. DTImax values for LUV-1 and SUV-1 were approximately 6, while the value for LUV-2 with a relatively large systemic clearance was only 2.3. The F values for LUV-1, LUV-2, and SUV-1 with hyperthermia were 0.71, 1.17, and 0.34, respectively, whereas the values for these liposomes without hyperthermia and for LUV-3 with or without hyperthermia were nearly zero. These results confirm earlier findings that LUV-1 and LUV-2 release CDDP almost completely at the heated tumor and that the large DTI value obtained in LUV-1 (DTI = 4.6) was due to its high heat sensitivity and its small systemic clearance.
为了评估热敏感脂质体在热疗给药后在肿瘤部位的药物释放速率和最大药物靶向性,我们推导了一种理论和实验方法,用于评估脂质体单次通过加热肿瘤时释放的药物比例F,以及药物完全因热释放时的药物靶向指数(F = 1时)DTImax。利用向荷瘤小鼠给药脂质体后血液中脂质体水平和肿瘤药物水平的报道数据,对四种脂质体(LUV - 1和LUV - 2,热敏感大单层脂质体;LUV - 3,非热敏感大单层脂质体;SUV - 1,热敏感小单层脂质体)的F和DTImax进行了评估。LUV - 1和SUV - 1的DTImax值约为6,而全身清除率相对较高的LUV - 2的值仅为2.3。热疗时LUV - 1、LUV - 2和SUV - 1的F值分别为0.71、1.17和0.34,而这些脂质体未进行热疗时以及LUV - 3无论有无热疗时的值几乎为零。这些结果证实了早期的发现,即LUV - 1和LUV - 2在加热的肿瘤部位几乎完全释放顺铂,并且LUV - 1中获得的高DTI值(DTI = 4.6)是由于其高热敏感性和小的全身清除率。